Client of a consultant lobbyist
RAREi - The Canadian Forum for Rare Disease Innovators
- Meetings this Parliament
- 2
- With MPs
- 1
- Since Nov 2021
- 11
- Active registrations
- 0
Most recent reported meeting: Oct 1, 2025.
Lobbying by RAREi - The Canadian Forum for Rare Disease Innovators: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
RAREi - The Canadian Forum for Rare Disease Innovators has no active registration. Organizations must register once paid lobbying passes the legal threshold, and their registration ends when it stops.
Reported meetings
Spreadsheet-
Reported by Stephanie Levee · Consultant
- Tom Kmiec · Member of Parliament
Bill C-64: An Act respecting pharmacare, with a particular focus on access to medicines and rare disease and orphan drug policies Read more
Engagement with officials on issues related to the National Strategy for Rare Disease Drugs, and other policies or programs related to rare diseases.
Regulatory amendments and/or guidelines and/or policies related to the Food and Drugs Act and Health Canada review of drugs for rare diseases.
Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals including any health technology assessment-related or other policy discussions that might involve Health Canada and its ongoing relationship with Canada's Drug Agency and/or other pan-Canadian health organizations.
Federally-funded public drug plans, with respect to reimbursement fof medicines for federal plan beneficiaries.
-
Reported by Stephanie Levee · Consultant
- Sandenga Yeba · Senior Policy Advisor, Health Canada (HC)
- Justine Frame · Policy Coordinator, Health Canada (HC)
Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals including any health technology assessment-related or other policy discussions that might involve Health Canada and its ongoing relationship with Canada's Drug Agency and/or other pan-Canadian health organizations. Read more
Engagement with officials on issues related to the National Strategy for Rare Disease Drugs, and other policies or programs related to rare diseases.
Federally-funded public drug plans, with respect to reimbursement fof medicines for federal plan beneficiaries.
Regulatory amendments and/or guidelines and/or policies related to the Food and Drugs Act and Health Canada review of drugs for rare diseases.
-
Reported by Stephanie Levee · Consultant
- Francesco Sorbara · Member of Parliment, House of Commons
BudgetHealthIndustryResearch and DevelopmentScience and Technology
-
Reported by Stephanie Levee · Consultant
- Mohamed-Iqbal Ravalia · Senator, Senate of Canada
BudgetHealthIndustryResearch and DevelopmentScience and Technology
-
Reported by Stephanie Levee · Consultant
- Stephen Ellis · MP for Cumberland—Colchester, House of Commons
Economic DevelopmentHealthIndustryIntellectual PropertyInternational TradeScience and TechnologyTaxation and Finance
-
Reported by Stephanie Levee · Consultant
- Michelle Mujoomdar · Director, Health Canada (HC)
Economic DevelopmentHealthIndustryIntellectual PropertyInternational TradeScience and TechnologyTaxation and Finance
-
Reported by Stephanie Levee · Consultant
- Adam van Koeverden · Member of Parliament
Economic DevelopmentHealthIndustryIntellectual PropertyInternational TradeScience and TechnologyTaxation and Finance
-
Reported by Stephanie Levee · Consultant
- Adam van Koeverden · Member of Parliament
Economic DevelopmentHealthIndustryIntellectual PropertyInternational TradeScience and TechnologyTaxation and Finance
-
Reported by Stephanie Levee · Consultant
- Brent Lawlor · Director, Health Canada (HC)
Economic DevelopmentHealthIndustryIntellectual PropertyInternational TradeScience and TechnologyTaxation and Finance
-
Reported by Stephanie Levee · Consultant
- Francesco Sorbara · Member of Parliment, House of Commons
Economic DevelopmentHealthIndustryIntellectual PropertyInternational TradeScience and TechnologyTaxation and Finance
-
Reported by Stephanie Levee · Consultant
- Holly Duggan · Manager of Stakeholder Relations, House of Commons
- Alexander MacDonald · Policy Advisor, House of Commons
Economic DevelopmentHealthIndustryIntellectual PropertyInternational TradeScience and TechnologyTaxation and Finance
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.